Jhaveri KL, Accordino MK, Bedard PL, Cervantes A, et al. Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer. J Clin Oncol 2024 Sep 5:JCO2400110. doi: 10.1200/JCO.24.00110.
PMID: 39236276